APA (7th ed.) Citation

M, B., A, G., G, U. K., C, I., A, B., O, B., . . . M, C. (2017). Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocrine research, 42(2), 145. https://doi.org/10.1080/07435800.2016.1255896

Chicago Style (17th ed.) Citation

M, Bicer, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O, Yuksel A, Bozkaya G, and Calan M. "Endocan Is a Predictor of Increased Cardiovascular Risk in Women with Polycystic Ovary Syndrome." Endocrine Research 42, no. 2 (2017): 145. https://doi.org/10.1080/07435800.2016.1255896.

MLA (9th ed.) Citation

M, Bicer, et al. "Endocan Is a Predictor of Increased Cardiovascular Risk in Women with Polycystic Ovary Syndrome." Endocrine Research, vol. 42, no. 2, 2017, p. 145, https://doi.org/10.1080/07435800.2016.1255896.